ClinicalTrials.gg
CompletedNCT00814125Updated May 1, 2009

ATAC - Endometrial Sub-Protocol

A Phase 3 interventional study of Anastrozole (Arimidex) and Tamoxifen (Nolvadex) in Breast Cancer, sponsored by AstraZeneca. Completed. Open to female participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2009-05-01.

Sponsored by AstraZeneca · Phase 3 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
45 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies testing anastrozole in Breast Neoplasms — 17 open to participants now, 28 under way, 10 of them phase 3. Anastrozole · Breast Neoplasms.

Enrollment
35th of 109
285 · median 148
Started
1997
the only one that year
Phase 3
38 of 111
5 open now
Registered
39th of 111
by date
Lead sponsor
16 of 111
AstraZeneca

Among the 111 studies testing anastrozole in Breast Neoplasms, this one is the 35th largest by enrollment of the 109 interventional ones that give a count, is the only one that started in 1997, is one of 38 in phase 3, and was the 39th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 111 studies testing anastrozole in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About anastrozole

Anastrozole: first FDA approval 1995 (ARIMIDEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 45 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies testing anastrozole in Breast Neoplasms, or all of them as a file.
02

Study summary

To compare the difference between the ARIMIDEX group and the tamoxifen group in the incidence of abnormal endometrial histological findings arising after treatment has commenced.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Endometrial
  • Endometrial histological findings
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients eligible for entry into the main ATAC trial (1033IL/0029)
  • Not received any previous tamoxifen, for whatever reason
  • Not undergone a hysterectomy and do not have a hysterectomy planned within the next 6 years
  • No previous endometrial ablation

Exclusion criteria

Exclusion Criteria:

  • Excluded from entry into the main ATAC trial (1033IL/0029). As detailed in Section 4.4 of the main ATAC trial (1033IL/0029)
05

Study design

Phase
Phase 3
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
285 participants (actual)

Study arms

  • Active comparator
    1

    Arimidex 1mg + Nolvadex placebo

    Drug: Anastrozole (Arimidex) · Drug: Nolvadex placebo

  • Active comparator
    2

    Arimidex placebo + Nolvadex 20mg

    Drug: Tamoxifen (Nolvadex) · Drug: Arimidex placebo

  • Active comparator
    3

    Arimidex 1mg + Nolvadex 20mg

    Drug: Anastrozole (Arimidex) · Drug: Tamoxifen (Nolvadex)

Interventions

06

What researchers measure

Primary outcomes

  1. Withdrawl

  2. Death

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 1997 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2008
First posted
Dec 24, 2008
Start
Jun 1997
CompletionActual
Dec 2005
Last update
May 1, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00814125
Lead sponsor
AstraZeneca
First posted
Dec 24, 2008
Start date
Jun 1997
Completion
Dec 2005
Last update
May 1, 2009

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anastrozole · Tamoxifen

Start the discussion